在皮肤冠状动脉干预后使用临床深度数据积累系统数据库对普拉苏格勒剂量的回顾性观察分析
Yukio Hiroi1, Yosuke Shimizu2, Yukari Uemura2
1Department of Cardiology, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Global health & medicine
|February 26, 2026
概括
在日本,较低的普拉苏格勒剂量 (2.5毫克) 可以在皮肤冠状动脉干预 (PCI) 后的特定患者群体中降低出血风险,而不会增加重大不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 普拉苏格勒在皮肤穿刺冠状动脉干预 (PCI) 后预防心血管事件方面是有效的.
- 在日本,最佳的普拉苏格勒剂量,特别是针对特定患者的人口统计数据,仍未得到充分研究.
研究的目的:
- 在接受PCI的日本患者中,比较不同剂量的普拉苏格勒 (2.5毫克与3.75毫克) 的有效性和安全性.
- 确定与较低普拉苏格勒剂量使用相关的患者特征,并评估临床结果.
主要方法:
- 使用临床深度数据积累系统 (CLIDAS-PCI) 数据库进行了回顾性观察性研究.
- 对PCI后用普拉苏格勒治疗的患者的2年随访数据的分析.
- 在接受2.5毫克和3.75毫克普拉苏格勒剂量的患者之间对结果的比较.
主要成果:
- 2.5毫克组包括更多的女性,老年人,体重较低的患者,以及那些患有诸如中风或恶性瘤等并发症的患者.
- 主要不良心脏和脑血管事件在两组之间是相似的.
- 2.5毫克组的非致命性中风和严重出血率较高.
结论:
- 普拉苏格勒2.5毫克在日本可能会被考虑给体重较低的患者,老年人,妇女,以及那些同时接受抗血栓治疗以减轻出血风险的患者.
- 在考虑PCI后降低普拉苏格勒剂量时,仔细选择患者至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Acute Coronary Syndrome III: Diagnostic Studies
338
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
338
Coronary Artery Disease V: Interprofessional Care
343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288

